col blocks we are bridge builder col blocks
COVID Antworten in den wissenschaftlichen Zeitschriften der Welt


45 Ergebisse       Seite 1

 [1] 
Elsevier: Bioorganic Chemistry
  Original Artikel Datum Titel Autoren   Alle Autoren
1 [GO] 2025―Aug―23 Inhibiting viral entry of bat-derived coronavirus HKU5-CoV-2: Targeting spike protein S1 subunit with FDA-approved antivirals-A structural dynamics and energetics study Amit Dubey, Manish Kumar, Aisha Tufail
2 [GO] 2025―Jul―04 Unveiling novel pharmacophores and hit compounds for the development of anti-virals to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Belén Dávila, Martín Fló, Santiago Ruatta, Franca Lorenzelli, Andrea Medeiros, Jonathan Bastidas, et al. (+14)
3 [GO] 2025―Mai―23 Tipranavir analogs as antiviral agents: Design, synthesis, in vitro, and in silico study of new SARS-CoV-2 main protease inhibitors Selwan M. El-Sayed, Dina I.A. Othman, Ghada S. Hassan, Ahmed H.E. Hassan, Shahenda M. El-Messery, Ahmed R. El-Sheakh
4 [GO] 2025―Apr―05 Synthesis of new selective agents with dual anti-inflammatory and SARS-CoV-2 Mpro inhibitory activity: Antipyrine-celecoxib hybrid analogues; COX-2, COVID-19 cytokine storm and replication inhibitory activities. Eman K.A. Abdelall, Heba A.H. Elshemy, Madlen B. Labib, John N. Philoppes, Fares E.M. Ali, Amira K.M. Ahmed
5 [GO] 2024―Dez―24 Buckyballs to fight pandemic: Water-soluble fullerene derivatives with pendant carboxylic groups emerge as a new family of promising SARS-CoV-2 inhibitors Olga A. Kraevaya, Valeriya S. Bolshakova, Alexander V. Slita, Iana L. Esaulkova, Alexander V. Zhilenkov, Mikhail G. Mikhalsky, et al. (+6)
6 [GO] 2024―Nov―22 A Glimpse for the subsistence from pandemic SARS-CoV-2 infection Santosh K. Rath, Ashutosh K. Dash, Nandan Sarkar, Mitali Panchpuri
7 [GO] 2024―Nov―19 Design, synthesis, and biological evaluation of novel AAK1/HDACs dual inhibitors against SARS-CoV-2 entry Nian-Dong Mao, Yueying Xu, Xia Yao, Yuan Gao, Zi Hui, Hao Che, et al. (+6)
8 [GO] 2024―Okt―28 Design, synthesis, and structure-activity relationships of xanthine derivatives as broad-spectrum inhibitors of coronavirus replication Xiaofang Chen, Xiaotian Ding, Cong Bian, Kun Wang, Xiao Zheng, Haiyan Yan, et al. (+8)
9 [GO] 2024―Okt―18 Identification of adenosine analogues as nsp14 N7-methyltransferase inhibitors for treating coronaviruses infection Qishu Chen, Qifan Zhou, Sidi Yang, Fan Pan, Hongqi Tao, Yuanmei Wen, et al. (+6)
10 [GO] 2024―Jun―28 Density functional theory and enzyme studies support interactions between angiotensin receptor blockers and angiotensin converting enzyme-2: Relevance to coronavirus 2019 Vasso Apostolopoulos, Nikitas Georgiou, Demeter Tzeli, Thomas Mavromoustakos, Graham J. Moore, Konstantinos Kelaidonis, et al. (+7)
11 [GO] 2024―Apr―17 A path from synthesis to emergency use authorization of molnupiravir as a COVID-19 therapy Norein Sakander, Ajaz Ahmed, Mahir Bhardwaj, Diksha Kumari, Utpal Nandi, Debaraj Mukherjee
12 [GO] 2024―Apr―16 Non-peptidic inhibitors targeting SARS-CoV-2 main protease: A review Ya-Qi Xiao, Jiao Long, Shuang-Shuang Zhang, Yuan-Yuan Zhu, Shuang-Xi Gu
13 [GO] 2024―Mrz―27 New meroterpenoids and polyketides from the endophytic fungus Paraphaeosphaeria sp. C-XB-J-1 and their anti-inflammatory and SARS-CoV-2 Mpro inhibitory activities Qi Li, Peng-Yun Yang, Chao Peng, Xing-Jie Zhang, Yun-Tao Jiang, Yan-Ping Li, Lu Gao
14 [GO] 2023―Dez―10 Enhancement efficiency delivery of antiviral Molnupiravir-drug via the loading with self-assembly nanoparticles of pycnogenol and cellulose which are decorated by zinc oxide nanoparticles for COVID-19 therapy Nagi M. El-Shafai, Yasser S. Mostafa, Mohamed S. Ramadan, Ibrahim El-Mehasseb
15 [GO] 2023―Dez―06 Discovery of α-Ketoamide inhibitors of SARS-CoV-2 main protease derived from quaternized P1 groups Qiao Huang, Baoxue Quan, Yan Chen, Xiu Zhao, Yanmei Zhou, Chong Huang, et al. (+6)
16 [GO] 2023―Sep―30 Synthesis, docking studies and biological evaluation of 1H-1,2,3-triazole-7-chloroquinoline derivatives against SARS-CoV-2 Jerome P.L. Ng, Yun Xiao Yun, Ali Adnan Nasim, Alessandra Gianoncelli, Betty Yuan Kwan Law, Giovanni Ribaudo, et al. (+2)
17 [GO] 2023―Sep―05 Discovery of new non-covalent and covalent inhibitors targeting SARS-CoV-2 papain-like protease and main protease Wandong Liu, Juan Wang, Suyun Wang, Kairui Yue, Yu Hu, Xiaochun Liu, et al. (+3)
18 [GO] 2023―Jan―28 Green and efficient one-pot three-component synthesis of novel drug-like furo[2,3-d]pyrimidines as potential active site inhibitors and putative allosteric hotspots modulators of both SARS-CoV-2 MPro and PLPro Hossein Mousavi, Behzad Zeynizadeh, Mehdi Rimaz
19 [GO] 2022―Nov―17 Exploring the dual effect of novel 1,4-diarylpyranopyrazoles as antiviral and anti-inflammatory for the management of SARS-CoV-2 and associated inflammatory symptoms Azizah M. Malebari, Hany E. A. Ahmed, Saleh K. Ihmaid, Abdelsattar M. Omar, Yosra A. Muhammad, Sultan S. Althagfan, et al. (+9)
20 [GO] 2022―Nov―09 Discovery and mechanism of action of Thonzonium bromide from an FDA-approved drug library with potent and broad-spectrum inhibitory activity against main proteases of human coronaviruses Ruyu Wang, Guanglei Zhai, Guanghao Zhu, Mengge Wang, Xiaoyi Gong, Weidong Zhang, et al. (+3)
21 [GO] 2022―Jun―26 Synthesis and Structure-Activity Relationship Study of Saponin-Based Membrane Fusion Inhibitors against SARS-CoV-2 Youngho Jang, Tai Young Kim, Sangeun Jeon, Hyeonggeun Lim, JinAh Lee, Seungtaek Kim, et al. (+2)
22 [GO] 2022―Mai―04 Synthesis, antimicrobial, molecular docking and molecular dynamics studies of lauroyl thymidine analogs against SARS-CoV-2: POM study and identification of the pharmacophore sites Mohammed Anowar Hosen, Nasrin Sultana Munia, Mohammed Al-Ghorbani, Mohammed Baashen, Faisal A. Almalki, Taibi Ben Hadda, et al. (+5)
23 [GO] 2022―Apr―18 Hydroxamate and thiosemicarbazone: two highly promising scaffolds for the development of SARS-CoV-2 antivirals Yin-Sui Xu, Jia-Zhu Chigan, Jia-Qi Li, Huan-Huan Ding, Le-Yun Sun, Lu Liu, et al. (+2)
24 [GO] 2022―Jan―01 In vitro Potential Antiviral SARS-CoV-19- Activity of Natural Product Thymohydroquinone and Dithymoquinone from Nigela sativia Eman R. Esharkawy, Faisal Almalki, Taibi Ben Hadda
25 [GO] 2021―Dez―21 Virtual screening and in vitro validation of natural compound inhibitors against SARS-CoV-2 spike protein Helen Power, Jiadai Wu, Stuart Turville, Anupriya Aggarwal, Peter Valtchev, Aaron Schindeler, Fariba Dehghani
26 [GO] 2021―Okt―30 The Mpro structure-based modifications of ebselen derivatives for improved antiviral activity against SARS-CoV-2 virus Zhen Qiao, Ningning Wei, Lin Jin, Hongyi Zhang, Jiajie Luo, Yanru Zhang, KeWei Wang
27 [GO] 2021―Sep―23 A Robust High-throughput Fluorescent Polarization Assay for the Evaluation and Screening of SARS-CoV-2 Fusion Inhibitors Xinjian Yin, Litong Chen, Siwen Yuan, Lan Liu, Zhizeng Gao
28 [GO] 2021―Aug―28 Polyketone metabolites isolated from Rhodiola tibetica endohytic fungus Alternaria sp. HJT-Y7 and their SARS-CoV-2 virus inhibitory activitives Xuan Lu, Xiao-Yuan Tang, Hai-Xin Wang, Wei-jin Huang, Wei-Xing Feng, Bao-Min Feng
29 [GO] 2021―Aug―24 Synthesis of Novel Calcium Channel Blockers with ACE2 inhibition and dual antihypertensive /Anti-Inflammatory Effects: A possible Therapeutic tool for COVID-19 Shahenda Mahgoub, Mohamed-I Kotb El-Sayed, Mohamed F. El-Shehry, Samir Mohamed Awad, Yara E. Mansour, Samar S. Fatahala
30 [GO] 2021―Jul―05 Pomegranate Peel Extract Polyphenols Attenuate the SARS-CoV-2 S-glycoprotein Binding Ability to ACE2 Receptor: In Silico and In Vitro Studies Relja Suručić, Maja Travar, Miroslav Petković, Miloš P. Stojiljković, Milkica Grabež, Katarina Šavikin, et al. (+2)
31 [GO] 2021―Jun―30 3-Alkenyl-2-oxindoles: Synthesis, antiproliferative and antiviral properties against SARS-CoV-2 Adel S. Girgis, Siva S. Panda, Aladdin M. Srour, Anwar Abdelnaser, Soad Nasr, Yassmin Moatasim, et al. (+11)
32 [GO] 2021―Jun―23 New quinoline-triazole conjugates: Synthesis, and antiviral properties against SARS-CoV-2 Israa A. Seliem, Siva S. Panda, Adel S. Girgis, Yassmin Moatasim, Ahmed Kandeil, Ahmed Mostafa, et al. (+8)
33 [GO] 2021―Mai―25 Potential drug development and therapeutic approaches for clinical intervention in COVID-19 Jayanta Dowarah, Brilliant N. Marak, Umesh Chand Singh Yadav, Ved Prakash Singh
34 [GO] 2021―Mai―05 Synthesis, molecular docking, and in silico ADMET studies of 4-benzyl-1-(2,4,6-trimethyl-benzyl)-piperidine: Potential Inhibitor of SARS-CoV2 R. Nandini Asha, B. Ravindran Durai Nayagam, Nattamai Bhuvanesh
35 [GO] 2021―Apr―08 Ebsulfur and Ebselen as highly potent scaffolds for the development of potential SARS-CoV-2 antivirals Le-Yun Sun, Cheng Chen, Jianpeng Su, Jia-Qi Li, Zhihui Jiang, Han Gao, et al. (+4)
36 [GO] 2021―Mrz―30 Novel inhibitors of the main protease enzyme of SARS-CoV-2 identified via molecular dynamics simulation-guided in vitro assay Jennifer Loschwitz, Anna Jäckering, Monika Keutmann, Maryam Olagunju, Raphael J. Eberle, Monika Aparecida Coronado, et al. (+2)
37 [GO] 2021―Feb―24 Discovery of Novel Inhibitors Against Main Protease (Mpro) of SARS-CoV-2 via Virtual Screening and Biochemical Evaluation Sheng Guo, Hang Xie, Yu Lei, Bin Liu, Li Zhang, Yechun Xu, Zhili Zuo
38 [GO] 2020―Nov―20 Computational Drug Discovery and Repurposing for the Treatment of COVID-19: A Systematic Review Kawthar Mohamed, Niloufar Yazdanpanah, Amene Saghazadeh, Nima Rezaei
39 [GO] 2020―Nov―20 Drug Repurposing for the Treatment of COVID-19: Pharmacological Aspects and Synthetic Approaches Pedro N. Batalha, Luana S.M. Forezi, Carolina G.S. Lima, Fernanda P. Pauli, Fernanda C.S. Boechat, Maria Cecília B.V. Souza, et al. (+3)
40 [GO] 2020―Okt―28 Measurement of oxidized albumin: An opportunity for diagnoses or treatment of COVID-19 Nasim Rahmani-Kukia, Ardeshir Abbasi, Nafiseh Pakravan, Zuhair Mohammad Hassan
41 [GO] 2020―Okt―07 Nano-sized Formazan analogues: Synthesis, structure elucidation, antimicrobial activity and Docking study for COVID-19 Huda K. Mahmoud, Basim H. Asghar, Marwa F. Harras, Thoraya A. Farghaly
42 [GO] 2020―Sep―29 A Perspective on Potential Target Proteins of COVID-19: Comparison with SARS-CoV for Designing New Small Molecules Devendra Kumar, Gaurav Chauhan, Sourav Kalra, Bhupinder Kumar, Manjinder Singh Gill
43 [GO] 2020―Sep―24 Role of heterocyclic compounds in SARS and SARS CoV-2 pandemic Meenakshi Negi, Pooja A Chawla, Abdul Faruk, Viney Chawla
44 [GO] 2020―Sep―08 Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19 Banoth Karan Kumar, Kondapalli Venkata Gowri Chandra Sekhar, Selvaraj Kunjiappan, Joazaizulfazli Jamalis, Rafael Balaña-Fouce, Babu L. Tekwani, Murugesan Sankaranarayanan
45 [GO] 2020―Sep―02 Is Oseltamivir suitable for fighting against COVID-19: in silico assessment, in vitro and retrospective study Qi Tan, Limin Duan, YanLing Ma, Feng Wu, Qi Huang, Kaimin Mao, et al. (+13)
 [1] 

45 Ergebisse       Seite 1


[de][en]

Letzte Änderung 2025―Jul―29 14:55:09 UTC

© Daten-Quadrat 2022       Done in 0.015 sec